Paper36968952
Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21).
Sader HS and 4 others. JAC Antimicrob Resist, 2023. Cited by 41 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21). Papers, record 36968952. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36968952
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21).
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14,506,051 | Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. | Antimicrob Agents Chemother | 2003 | https://conductscience.org/library/papers/14506051 | PubMed |
| 2 | 30,895,209 | The Importance of Antimicrobial Resistance Monitoring Worldwide and the Origins of SENTRY Antimicrobial Surveillance Program. | Open Forum Infect Dis | 2019 | https://conductscience.org/library/papers/30895209 | PubMed |
| 3 | 28,630,192 | In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28630192 | PubMed |
| 4 | 27,939,093 | Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission. | Int J Antimicrob Agents | 2017 | https://conductscience.org/library/papers/27939093 | PubMed |
| 5 | 35,372,099 | Global Threat of Carbapenem-Resistant Gram-Negative Bacteria. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/35372099 | PubMed |
| 6 | 32,387,260 | Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: A single-centre study. | J Glob Antimicrob Resist | 2020 | https://conductscience.org/library/papers/32387260 | PubMed |
| 7 | 22,506,599 | SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. | J Comput Biol | 2012 | https://conductscience.org/library/papers/22506599 | PubMed |
| 8 | 34,379,310 | Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. | Infect Dis Ther | 2021 | https://conductscience.org/library/papers/34379310 | PubMed |
| 9 | 34,436,603 | Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. | J Antimicrob Chemother | 2021 | https://conductscience.org/library/papers/34436603 | PubMed |
| 10 | 32,427,286 | Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/32427286 | PubMed |
| 11 | 20,003,500 | BLAST+: architecture and applications. | BMC Bioinformatics | 2009 | https://conductscience.org/library/papers/20003500 | PubMed |
| 12 | 35,669,117 | Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/35669117 | PubMed |
| 13 | 32,417,206 | Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. | Int J Antimicrob Agents | 2020 | https://conductscience.org/library/papers/32417206 | PubMed |
| 14 | 31,828,337 | Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. | J Antimicrob Chemother | 2020 | https://conductscience.org/library/papers/31828337 | PubMed |
| 15 | 25,267,671 | Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel β-lactamases, GES-22 and VIM-35. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/25267671 | PubMed |
| 16 | 26,926,646 | Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition. | Antimicrob Agents Chemother | 2016 | https://conductscience.org/library/papers/26926646 | PubMed |
| 17 | 32,988,825 | Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/32988825 | PubMed |
| 18 | 32,102,899 | Epidemiology of β-Lactamase-Producing Pathogens. | Clin Microbiol Rev | 2020 | https://conductscience.org/library/papers/32102899 | PubMed |
| 19 | 3,512,234 | Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. | Drugs | 1986 | https://conductscience.org/library/papers/3512234 | PubMed |
| 20 | 32,855,986 | The Clinical and Molecular Epidemiology of Noncarbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae: A Case-Case-Control Matched Analysis. | Open Forum Infect Dis | 2020 | https://conductscience.org/library/papers/32855986 | PubMed |
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,938,683 | In Vitro Activity of Eravacycline, Aztreonam-Avibactam, and Cefiderocol Against Multidrug-Resistant Gram-Negative Clinical Isolates from a Romanian Tertiary Hospital. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42938683 | PubMed |
| 42,714,383 | Impact of PBP3 insertions and β-lactamase-encoding genes on the susceptibility of Escherichia coli isolates belonging to high-risk clones against aztreonam-avibactam and comparator agents. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/42714383 | PubMed |
| 42,379,811 | In vitro activity of aztreonam-avibactam and comparators against Enterobacterales isolated from bloodstream infections: ATLAS/ surveillance, 2021-2022. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/42379811 | PubMed |
| 41,868,017 | Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations. | Infect Drug Resist | 2026 | https://conductscience.org/library/papers/41868017 | PubMed |
| 41,347,523 | Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-β-lactamase-producing Enterobacterales. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/41347523 | PubMed |
| 41,258,612 | Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms. | Drugs | 2026 | https://conductscience.org/library/papers/41258612 | PubMed |
| 40,981,473 | Molecular characterization of carbapenem-resistant Enterobacterales (CRE) and in vitro activity of novel beta lactams against CRE isolates from Malaysia. | Microbiol Spectr | 2025 | https://conductscience.org/library/papers/40981473 | PubMed |
| 40,727,714 | Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE). | JAC Antimicrob Resist | 2025 | https://conductscience.org/library/papers/40727714 | PubMed |
| 40,530,972 | Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/40530972 | PubMed |
| 40,172,627 | Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms. | Arch Microbiol | 2025 | https://conductscience.org/library/papers/40172627 | PubMed |
| 39,918,316 | Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime-avibactam in combination. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/39918316 | PubMed |
| 39,774,263 | Aztreonam-avibactam: a new combination with activity against multidrug-resistant Klebsiella pneumoniae complex. | J Antibiot (Tokyo) | 2025 | https://conductscience.org/library/papers/39774263 | PubMed |
| 39,766,529 | National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39766529 | PubMed |
| 39,384,682 | In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series. | Eur J Clin Microbiol Infect Dis | 2024 | https://conductscience.org/library/papers/39384682 | PubMed |
| 39,352,652 | Navigating the Current Treatment Landscape of Metallo-β-Lactamase-Producing Gram-Negative Infections: What are the Limitations? | Infect Dis Ther | 2024 | https://conductscience.org/library/papers/39352652 | PubMed |
| 39,292,563 | Gut microbiota-derived butyrate selectively interferes with growth of carbapenem-resistant Escherichia coli based on their resistance mechanism. | Gut Microbes | 2024 | https://conductscience.org/library/papers/39292563 | PubMed |
| 39,200,065 | Practical Application of Aztreonam-Avibactam as a Treatment Strategy for Ambler Class B Metallo-β-Lactamase Producing Enterobacteriaceae. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39200065 | PubMed |
| 38,800,756 | Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review. | Front Microbiol | 2024 | https://conductscience.org/library/papers/38800756 | PubMed |
| 38,399,502 | Carbapenem-Resistant Enterobacteriaceae in Urinary Tract Infections: From Biological Insights to Emerging Therapeutic Alternatives. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/38399502 | PubMed |
| 38,252,170 | Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation. | Eur J Clin Pharmacol | 2024 | https://conductscience.org/library/papers/38252170 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MBL3P | 50,639 | PubTator's text mining | https://conductscience.org/library/genes/50639 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36968952
GET https://conductscience.org/api/papers/v1/36968952/references?page=2